<\/p>\n
The neuro-protective effect of antenatal\u00a0magnesium sulfate<\/span>\u00a0on very preterm infants has been demonstrated in good-quality randomised controlled trials and meta-analyses.\u00a0Magnesium<\/span>\u00a0administered prior to preterm delivery crosses over to the foetal circulation and acts via several pathways to reduce perinatal neuronal damage. Meta-analysis of the trial data indicates that antenatal\u00a0magnesium sulfate<\/span>\u00a0reduces the risk of cerebral palsy by one-third, and results in one fewer case in every 50 women treated. Treatment is associated with discomfort and flushing in some women, but maternal side-effects are mostly transient and manageable.\u00a0Magnesium sulfate<\/span>\u00a0has also been found to be without any serious adverse consequences in newborn infants. Consensus recommendations and guidelines have been developed and implemented internationally, and endorsed by the UK Royal College of Obstetricians and Gynaecologists. However,\u00a0magnesium sulfate<\/span>\u00a0for neuro-protection of very preterm infants has not yet become established widely in UK practice. Paediatricians, neonatologists and advocacy groups for preterm infants and their families could contribute to raising awareness and engage in dissemination activities and implementation initiatives to develop local protocols for adoption of this safe, effective and cost-effective intervention to reduce the burden of cerebral palsy in children born very preterm.<\/p>\n<\/div>\n<\/div>\n Evidence Based Medicine; Multidisciplinary team-care; Neonatology; Neurodevelopment; Neurodisability<\/p>\n<\/div>\nKEYWORDS:<\/h4>\n